NASH/MASH
Metabolic Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Akero TherapeuticsEfruxifermin
Clinical Trials (1)
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Start: Nov 2023Est. completion: Oct 2026
Phase 3Active Not Recruiting
Related Jobs in Metabolic Diseases
Manager, Patient Safety and Pharmacovigilance Operations
Kailera Therapeutics
Waltham, Massachusetts
6h ago
Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV
Amgen
California - San Francisco, US
Yesterday
(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)
Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago
Computational Chemist
Topos Bio
San Francisco Office
2d ago
Associate Director, Legal Operations & Contracts Management
Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr
Diagnostics Value Consultant(Product Marketing) - Diabetes Care Portfolio
Roche
Taipei
5d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space